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1. Introduction 
1.1 Epidemiology and bladder carcinogenesis 
Cancer represents phenotypic manifestations of abnormal gene expression. Genetic 
mutations, dysregulation, and gene losses can influence cell proliferation and 
differentiation, and eventually lead to formation of cancer. Risk factors and etiologic agents 
involved in the genetic abnormalities influence the distribution of cancer worldwide. This 
chapter aims at highlighting the epidemiologic significance of urothelial bladder cancer; 
reviewing its natural history, the roles of industrial and environmental carcinogens and life 
style factors in urothelial carcinogenesis; and framing possible strategies for 
chemoprevention in the management of human urothelial cancer of the urinary bladder. 
Bladder cancer remains a serious public health problem worldwide, and accounts for 5-10% 
of all malignancies annually in western countries (Cancer Treatment of America). Though the 
age-adjusted incidence varies in the different parts of the world, the highest rates are found 
in men from North America (23.3/100,000), North Africa (23.3/100,000) and Southern 
Europe (22.0/100,000), while the corresponding rates are 5.4, 4.8, and 3.2 per 100000 for 
women (Cancer Treatment of America). These high rates may be influenced by increased 
industrialization, cigarette smoking, and infection of schistosomiasis (primarily of concern 
in North Africa). The lowest rates for both sexes have been reported for the Melanesia 
region of South Pacific and Middle Africa (Cancer Treatment of America; Prout, Barton et al. 
1992; Grasso 2008; American Cancer Society 2010). 
Bladder cancer, which is immensely impacted by environmental carcinogens and tobacco 
smokes, remains a common disease in the United States, and it is estimated that 70, 530 
persons (52,760 men and 17,770 women) were diagnosed with cancer of the urinary bladder 
in 2010, (Cancer Treatment of America; American Cancer Society 2010) and an estimated 14, 680 
died of the disease accounting for 3% and 2% of all cancer deaths in men and women, 
respectively (Cancer Treatment of America; American Cancer Society 2010). Estimates of new 
cancer cases classify urothelial bladder cancer (UBC) as the fourth most common in men and 
the eighth most common in women. The prevalence of UBC in the US is estimated at about 
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one million cases annually, and worldwide, UBC ranks as the ninth most frequent cancer 
(Cancer Treatment of America; Prout, Barton et al. 1992; Grasso 2008; American Cancer Society 
2010).  
Bladder cancer is a disease of aging; the incidence of UBC rises with age with an average of 
onset at 69 for men and 67 for women (Cancer Treatment of America; Prout, Barton et al. 1992; 
Dalbagni and Herr 2000; Grasso 2008; American Cancer Society 2010). Bladder cancer that 
occurs at ages 40 or younger tends to be low grade Ta cancer with almost negligible 
recurrence potential. Given sufficient time, however 50-70% of UBC patients will develop 
recurrent disease. Recurrences tend to be characterized by multiplicity in time and space, 
primarily if the initial tumors occurred early in life and were large or multiple in numbers. 
A majority, 70-75%, of UBC are superficial, that is, non-muscle invasive, and non-lethal, but 
they are characterized by frequent recurrences. However, the remaining 25-30% of the 
annual cases of UBC invades into the muscular propria, making them life threatening, 
because approximately 50% harbor micro-metastases that often manifest within three years 
out from diagnosis (Droller 2006).  
The non-muscle invasive UBC (NMIUBC) that are confined to the mucosa/urothelium Ta, 
remain non-lethal with a progression rate of less than 5%, and occur often as large or 
multiple tumors. Ten to twenty percent of the superficially-invasive UBC that is confined to 
the lamina propria, T1, converts to muscle invasive disease on repeat resection (Dalbagni 
and Herr 2000).  
Variable morphology, natural history, and prognosis demonstrate that transitional cell 
carcinoma (TCC) or urothelial carcinoma (UC) of the bladder is not a single disease, but 
occurs in three distinct forms, each possessing characteristic features that include low grade 
papillary, noninvasive; carcinoma in situ (CIS); and high grade, invasive (Grasso 2008). 
Seventy to eighty-five percent of new bladder cancer cases, are superficial or non-muscle 
invasive UBC, which include disease confined to the mucosa in CIS: CIS (10%), and Ta (70%), 
or lamina propria in T1 (20%) (Prout, Barton et al. 1992; Dalbagni and Herr 2000; Droller 
2006; Grasso 2008). These types of tumors are considered to have variable invasive potential 
with a progression rate to invasive cancer of 15% to 50% (Prout, Barton et al. 1992; Dalbagni 
and Herr 2000; Grasso 2008). However, more than 70% of patients with NMIUBC have one 
or more recurrences within 5 years of initial diagnosis (Prout, Barton et al. 1992; Dalbagni 
and Herr 2000; Droller 2006; Grasso 2008). Further analysis shows that approximately 50% 
of patients diagnosed with solitary bladder cancer will experience recurrences within 4 
years, while 70% of multiple bladder tumors reoccur within one year (Prout, Barton et al. 
1992; Dalbagni and Herr 2000; Droller 2006; Grasso 2008).  
The fact that the bladder serves as a reservoir for urine and its waste product contents 
predisposes it to the constant cumulative exposure to carcinogens which include industrial 
toxins and cigarette smoke chemicals. The multiple-step process of carcinogenesis includes 
induction/activation, promotion and progression, which exists as a continuum in the 
bladder environment. Consequently, preventive intervention can be difficult to implement 
under these conditions of cumulative exposures, and the definitive strategy will be to 
minimize constant cumulative exposure of carcinogenic agents from smoking and industrial 
sources. Increased carcinogenic exposure by itself cannot explain the 40% increase in 
bladder cancer incidence in the last 15 years in the US. The explanation certainly includes 
increased smoking that has added a large population of women, cumulative industrial 
exposure, and host factors. These host characteristics are likely to influence racial differences 
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in the incidence of bladder cancer. Caucasians have overall bladder cancer risk of 3.9% 
versus 0.8% overall chance in African Americans: 2.8% in men and 1.5% in women (Droller 
2006).  
Earliest reported association of industrial carcinogenic exposure and development of 
bladder cancer was by Rehn (Dietrich and Dietrich 2001). Observations have also 
documented associations between carcinogen ingestion in animals and development of 
bladder cancer (Okey, Harper et al. 1998; Sporn and Lippman 2003). Several legislative 
measures have been implemented in an attempt to decrease the intensity and cumulative 
nature of the carcinogen exposure. However, cigarette smoking trumps all considerations of 
environmental and industrial exposure and is the major factor underlying the spread and 
occurrence of bladder cancer around the globe.  
It is estimated that 30% of bladder cancer mortality is attributable to a history of tobacco 
abuse/dependence (American Cancer Society), and studies have tried to characterize the 
different carcinogenic agents in cigarette smoke that define the causal relationship between 
smoking and development of urothelial cancer (American Cancer Society; Droller 2006). 
Investigators have tried to correlate bladder cancer risk with the manufacturing processes 
such as the type of filter used, type of tobacco used, and the curing technique: black versus 
blonde (Droller 2006). The curing technique determines the concentration of the carcinogens 
in the cigarette. The smoke of black (air-cured) versus blonde (flue-cured) has been analyzed 
to show higher concentration of carcinogens in black tobacco. How these commercial 
practices influence urothelial carcinogenesis remains to be elucidated. 
Several specific carcinogens in cigarette smoke have been implicated in the development of 
urothelial cancer, including polycyclic aromatic hydrocarbons, aromatic and aryl amines 
(including 4-amino biphenyl), unsaturated aldehydes (e.g. acrolein) and oxygen-free radicals 
(American Cancer Society; Sabichi and Lippman; Droller 2006). Aromatic amines were the first 
carbon compounds of industrial by-products that were suspected in work- related urothelial 
cancer, found primarily in those workers who were exposed to the dye, rubber, and plastic 
manufacturing. These epidemiological data suggest up to 100-fold increased risk that is 
mediated by cumulative intensity and duration of exposure. Regulatory and legislative efforts 
to retard the work place risk contributed to the birth of occupational safety and health 
administration in the industrialized countries around the world. 
In spite of extensive efforts since then to curb workplace exposure to industrial carcinogens, 
textile, dry cleaning, hair dressing, and coal gasification continue to generate the 
carcinogens in the manufacturing process. The culprit agents are per-chloroethylene (an 
organic solvent used in dry cleaning), chemical dyes, aromatic amines (used in textile 
industry), and hair dyes that contain chemical carcinogens. These agents have been 
associated with bladder cancer development. Other carcinogens, outside of the workplace, 
that have been associated with the development of urothelial cancer include arsenic in 
ground water in southeastern Michigan in the US and southwestern Taiwan (Haack, 
Treccani et al. 2000; Kim, Nriagu et al. 2000; Welch, Westjohn et al. 2000; Droller 2006); 
ingestion of fang chi (Chinese herb used in weight control); ingestion of ochratoxin A in the 
Balkan countries resulting indirectly from animals that consumed blackened fern (Droller 
2006). Several medications and medical therapies have also been associated with urothelial 
cancer development including phenacetin used to treat headaches, cyclophosphamide 
(cytoxan) used to treat pediatric and adult hematologic malignancies (lymphoma and 
leukemia), and pelvic radiation for cervical and prostate cancer. 
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In parts of the world with endemicity, there are reports of association between Schistosoma 
haematobium infection and the development of urothelial cancer, primarily squamous cell 
carcinoma, and some cases of transitional cell cancer (Sabichi and Lippman; Okey, Harper et 
al. 1998; Sporn and Lippman 2003; Droller 2006). The inciting factors include an 
inflammatory response to the deposited parasitic ova of Schistosoma haematobium in the 
periurethral areas of the bladder ,as well as conversion of nitrates to nitrites with the 
nitrosamines mediating the development of urothelial cancer. Other carcinogenic exposures 
such as fertilizers and cigarette smoke may also play putative roles in the urothelial 
carcinogenesis in these patients.  
In urothelial carcinogenesis, several host factors have been recognized as playing either 
permissive or protective roles. Acetylation of aromatic amines remains an important 
mechanism of carcinogenic inactivation in urothelial carcinogenesis. The detoxification of 
carcinogens is mediated by genes namely NAT1 and NAT2 which are responsible for 
generating the detoxifying enzymes N-acetyl transferase, and NAT2 remains the 
predominant gene involved. Individuals who are homozygous for NAT2 are classified as 
slow acylators and they detoxify carcinogens quite slowly allowing prolonged contact with 
DNA to induce mutations and carcinogenesis (Sabichi and Lippman; Weber 1987; Droller 
2006). These individuals have a two- to four-fold increased risk for the development of 
urothelial cancer. On the other hand, the heterozygous fast acylators are able to rapidly 
detoxify these aromatic amines that lower their risk of developing urothelial cancer. 
Researchers have suggested that the potential differences in racial and ethnic risk of 
urothelial cancer development are attributable to the difference in the expression of these 
two genes (Sabichi and Lippman; Weber 1987; Droller 2006; Lattouf 2009).The P450 
cytochrome oxidase system is also important in metabolism and detoxification of urothelial 
carcinogens. The CYP1A2 might be particularly important in metabolizing aromatic amines 
(Sabichi and Lippman; Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 2006). 
Also, individuals deficient in the enzyme glutathione transferase may be at risk for deficient 
metabolism of polycyclic aromatic amines, which could put them at a 30-50% risk of 
developing bladder cancer (Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 
2006). 
2. Molecular biology of carcinogenesis and chemoprevention 
The classic multistep process of carcinogenesis which has been widely accepted includes 
initiation, promotion, and progression. A clear-cut sequential compartmentalization 
probably does not always occur, but the multistep structure could be exploited strategically 
for chemopreventative measures. The first step, initiation, depends upon three cellular 
functions, namely carcinogen metabolism, DNA repair, and cell proliferation. Cell damage 
can occur by activation/deactivation mediated by the carcinogen; this cell can cycle through 
DNA repair or exists as an altered gene (no tumor development) and can be propagated as 
such, or go through cell proliferation. In the promotion phase, the altered cell continues to 
undergo repeated bombardment by the promoter agent (initiator or not) leading to 
additional genomic damage and subsequent clonal expansion into a tumor. In the 
progression phase, the tumor acquires multicellular defective mutations enhanced by 
acquired or inherited mutations in the control genes such as p53, Rb, or DNA mismatch 
repairs (Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 2006). Consequently a 
tumor is born that lacks cellular growth controls, and has proliferative autonomy. The 
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challenge in designing a preventive strategy is selecting whether to target genomic or 
cellular events as well as determining the order of subsequent sequential targeting.  
Genotoxic carcinogens can be enzymatically bioactivated and converted into water soluble 
metabolites to be excreted in urine or bile. These carcinogens can also be inadvertently 
transformed into electrophiles which react with DNA. Metabolism of carcinogens or broadly 
biotransformation may depend upon genetic and environmental factors in an individual 
who is exposed to the carcinogens. The drug metabolizing enzymes are classified into Phase 
I and Phase II enzymes, with Phase I enzyme being primarily typified by cytochrome P450 
mono-oxygenase (CYP) super family. These enzymes function by unmasking the parent 
substrates (Okey, Harper et al. 1998; Sporn and Lippman 2003; Droller 2006). The Phase II 
enzymes including sulfotransferase, glutathione transferase (GST), and acetyltransferase 
primarily detoxify reactive metabolites. They catalyze the conjugation of bulky water 
insoluble components into hydroxyl groups which can easily be excreted. 
As discussed above, carcinogenesis is a multistep process; therefore chemopreventive agents 
could affect different mechanisms. In practice chemoprevention would require continuous 
administration of a non-toxic compound over a long period or lifetime of the at-risk 
individual. However, the chemoprevention strategy would begin with the population 
approach that advocates a dietary program of increased consumption of fruits and 
vegetables which have been reported to reduce general cancer risk (Sabichi and Lippman; 
Sporn and Lippman 2003; Lattouf 2009). At the individual level, the approach would be to 
reduce the intensity of cumulative exposure through programs that include 
reduction/elimination of exposure to the carcinogens, dilution and elimination of bladder 
content by drinking plenty of water and urinating frequently, followed by introduction of 
the at-risk individual to the chemopreventive agent(s). The potential chemoprevention 
agents can be broadly classified into two categories: (a) agents that decrease bioactivation or 
increase detoxification of carcinogens, and (b) agents that alter promotion and progression 
(Okey, Harper et al. 1998; Sporn and Lippman 2003). 
2.1 Agents that decrease bioactivation or increase detoxification of carcinogens 
The cytochrome P450 enzyme family, which typifies the Phase I enzymes, acts 
bidirectionally by bioactivating procarcinogens into reactive metabolites that bind to DNA, 
but also enhances overall clearance of both the procarcinogens and carcinogens from the 
body. The first pass clearance of the carcinogen by the high activity of P450 enzymes in the 
human liver exposes the susceptible peripheral organ/ tissue to reduced concentrations of 
the carcinogens (Okey, Harper et al. 1998; Sporn and Lippman 2003)..  
In bladder cancer, the Phase II enzymes include the detoxifier glutathione transferases 
which conjugate reactive metabolites with glutathione. These Phase II enzymes can be 
induced by plant products such as sulforaphane from broccoli. This induction can be 
highly protective in animals against major carcinogens. However, they can also act 
bidirectionally to favor Phase I class of enzymes (Okey, Harper et al. 1998; Sporn and 
Lippman 2003). 
Interestingly, oltipraz, an anti-schistosomiasis drug, functions bidirectionally to inhibit the 
predominant activating enzyme CYPIA2, and also induces a glutathione S-transferase Phase 
II enzyme that detoxifies carcinogens by conjugation. Another cytochrome P450 modulator 
is indole-3-carbinole (I3C) which is abundant in broccoli, brussels sprouts, and cruciferous 
vegetables (Okey, Harper et al. 1998; Sporn and Lippman 2003). 
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The phytochemicals that reduce adduct formation include vitamin E (-tocopherol) and 
vitamin C (ascorbic acid). These act as scavengers of the reactive metabolites, or act as 
antioxidants (Okey, Harper et al. 1998; Sporn and Lippman 2003). However, they have not 
been found to decrease the risk of cancer in high-risk populations.  
2.2 Agents that alter promotion and progression 
Inflammation, increased cell proliferation/decreased differentiation, deficiency of apoptosis, 
and cumulative genetic instability constitute putative molecular and cellular events that 
induce promotion and progression during carcinogenesis (Okey, Harper et al. 1998; Sporn 
and Lippman 2003; Droller 2006). These cellular events are attractive potential targets for 
chemopreventative intervention.  
Synthetic retinoids have been shown to alter gene expression and stimulate apoptosis. 
However, these have failed as primary chemopreventive agents, but have been shown to 
delay the appearance of secondary primary cancers of head and neck (Sabichi and Lippman; 
Okey, Harper et al. 1998; Sporn and Lippman 2003). However, natural retinoids such as -
carotene have shown a paradoxical increase in lung cancer in smokers and asbestos-exposed 
workers.  
Targeting inflammation has become an attractive approach in chemoprevention as scientists 
gain better understanding of the association between inflammation and increased cancer 
risk, particularly colon cancer. Both the older-generation non-specific inhibitors of 
cyclooxygenase including: aspirin and non-steroidal anti-inflammatory agents (NSAIDS) 
and the newer synthetic selective COX-2 inhibitors such as Celecoxib have shown promising 
results in preventing colon cancer in rodent models and in humans(Sporn and Lippman 
2003).  
3. Conventional strategies in preventing recurrence/occurrence and 
progression  
Approaches to bladder cancer prevention include primary prevention which aims at 
avoiding cancer development in healthy populations, secondary prevention, which aims at 
preventing premalignant lesions from undergoing promotion and progression into cancer 
under conducive conditions during carcinogenesis; and tertiary prevention, which aims at 
aborting cancer progression in patients who have been treated for the cancer. In bladder 
cancer, primary prevention is widely regarded as impractical. Even if good 
chemopreventive agents were available the risk-benefit ratio would have to be low in such a 
large at risk population. The other challenges to primary intervention strategy are discussed 
in the sections above about the uncertainty of appropriate molecular/cellular targets to 
prevent tumor initiation. In practice techniques of secondary and tertiary prevention are 
indistinguishable. 
Following the initial diagnosis with transurethral resection of bladder tumor (TURBT), there 
are several interventions that may be undertaken to retard cancer recurrence and 
progression: selected patients may undergo repeat TURBT to better delineate the nature of 
their disease (Prout, Barton et al. 1992; Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et 
al. 1995; Dalbagni and Herr 2000), approximately 20% will receive intravesical 
chemotherapy to potentially eradicate residual disease (Prout, Barton et al. 1992; 
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Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000) and 
the majority will be placed on some type of endoscopic surveillance schedule. The necessity 
for early adjuvant treatment, mainly intravesical instillation of immunotherapeutic or 
chemotherapeutic agents in the management of high-risk CIS, Ta/high grade and T1/any 
grade is recognized globally (Prout, Barton et al. 1992; Oosterlinck, Kurth et al. 1993; Lamm, 
Blumenstein et al. 1995; Dalbagni and Herr 2000). The hope is that this treatment, by altering 
the neoplastic potential of the urothelium, will reduce the risk for recurrence and 
progression. The subsets of the patients with NMIUBC who fail the conventional 
intravesical therapies will ultimately be subjected to radical cystectomy with resultant loss 
of bladder function, body image and sexual function (Prout, Barton et al. 1992; Oosterlinck, 
Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000). The newest 
strategy in the management of NMIUBC is Photodynamic Diagnosis (PDD) with Hexvix 
(PhotoCure ASA, Oslo, Norway) to minimize recurrences/occurrences and progression. PPD 
uses Hexvix which is an ester derivative of 5-Aminolevulinic Acid (ALA) (Jichlinski, Guillou 
et al. 2003; Fradet, Grossman et al. 2007) was recently approved by the US Food and Drug 
Administration (FDA) for management of NMIUBC primarily to improve the diagnostic 
and staging accuracy of cystoscopy leading to improvement in survival. Photodynamic 
diagnosis occurs when a photosensitizing agent is first concentrated in malignant or 
abnormal tissue, and then activated by light (Henderson 1992). The activated 
photosensitizer either returns to ground state, and releases energy as fluorescence, which 
can be used in detection (PDD), or the photosensitizer enters into its triplet state, and causes 
physico-chemical reactions to generate reactive oxygen species (ROS), for therapy as in 
Photodynamic therapy (PDT). Hexvix-PDD has been reported to improve the diagnostic 
rate of Ta and T1 papillary bladder cancers by 16.4% and the detection of CIS by 31% (as 
compared to white light cystoscopy) (Jichlinski, Guillou et al. 2003). Recently, Karl et al., 
reported that PDD during initial TURBT for T1G3 NMBIC exhibited a significant reduction 
in recurrence rate; led to detection of additional 35.4% CIS versus 21.8% in the control group 
(standard white light TURBT).The authors concluded that the initial use of PDD-directed 
TURBT could provide a superior cancer control and effective treatment of patients with 
T1G3 NMIBC (Karl 2010). 
Bacillus Calmette-Guerin (BCG), an immunotherapy, remains the most effective and widely 
used intravesical agent to prevent recurrence and progression (Oosterlinck, Kurth et al. 
1993; Lamm, Blumenstein et al. 1995; Dalbagni and Herr 2000). Mitomycin, thiotepa and 
epirubicin are the commonly used intravesical chemotherapeutic agents. while intravesical 
Valrubicin is FDA-approved as an alternative intravesical therapy to radical cystectomy for 
BCG refractory CIS patients (Dalbagni and Herr 2000). Administering Mitomycin or 
epirubicin immediately following TURBT has been reported as effective in preventing 
tumor implant; however, this approach has failed to ultimately prevent disease progression 
or mortality (Oosterlinck, Kurth et al. 1993). Of course, each intravesical agent is associated 
with both local and systemic side effects. Despite current treatment strategies, 30-80% of 
these patients develop recurrences within 5 years, and this high rate of recurrence of NMIBC 
invariably leads to a high economic impact (Hedelin, Holmang et al. 2002; Botteman, Pashos 
et al. 2003; Uchida, Yonou et al. 2007; Hong and Loughlin 2008; Sievert, Amend et al. 2009). 
The disease progression rate to muscle invasiveness is 42-83% in BCG-treated patients who 
have concomitant CIS and papillary NMIUBC, and 30-50% in those BCG-treated patients 
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with primary CIS (Oosterlinck, Kurth et al. 1993; Lamm, Blumenstein et al. 1995; Dalbagni 
and Herr 2000). Frequent follow ups and re-treatment of patients due to the recurrences 
exert heavy untold burden on the affected patients; eventually leading to morbidity as well 
as increased expenditure because of continuous treatment (Hedelin, Holmang et al. 2002; 
Botteman, Pashos et al. 2003; Uchida, Yonou et al. 2007; Hong and Loughlin 2008; Sievert, 
Amend et al. 2009). 
3.1 Chemoprevention in the armamentarium of management of NMIUBC 
Early detection and advances in treatments over the last two decades have resulted in an 
overall reduction in bladder cancer mortality (Cancer Treatment of America; American 
Cancer Society 2010). The public health and socioeconomic burden of bladder cancer could 
be reduced through practice of systematic prevention measures including 
elimination/minimization of exposure to carcinogens, hydration for dilution and frequent 
urination to expulse potential carcinogens; and practice of active dietary and/or 
pharmacologic preventative interventions. Unfortunately, in bladder cancer there are still no 
definite interventions that have been shown to be effective, and research in this area has 
yielded no evidence-based data to inform on strategies for systematic practice of bladder 
cancer prevention. Bladder urothelial cancer has biologic and clinical characteristics that 
favor it as an ideal cancer for chemoprevention. These special features include its 
susceptibility; carcinogenesis; frequent recurrences, and clinical presentation.  
3.2 Cessation of smoking 
The most cost-effective measure in bladder cancer prevention strategy would certainly be 
smoking cessation. This, of course, would be very difficult because of the addictive nature of 
the current cadre of manufactured cigarettes. In the meantime therapeutic intervention is 
needed to complement and perhaps even supplant the current socio-cultural as well as the 
legislative strategies to reduce the economic burden, suffering and death from bladder 
cancer through tobacco control. In the following section we will review the available 
evidence for the various chemotherapeutic agents. 
4. Bladder cancer chemoprevention strategies: Non-pharmacologic and 
dietary approach (see also Table 1) 
4.1 Fluid intake  
The Health Professional Follow Up Study validated the concept that increased fluid intake 
could substantially lower the risk of UBC due to lowered intensity and cumulative exposure 
of carcinogens (Michaud, Spiegelman et al. 1999). The study involved mailing 
questionnaires to 47,903 men; and analysis of their responses regarding daily fluid intake. 
The data showed inverse association between total daily fluid intake and risk of urothelial 
cancer (UC) with a relative risk of 0.51 (0.32-0.81, 95% confidence interval: CI) in those who 
consumed the largest amount of fluid. Daily water consumption offered the best protection 
when compared with other fluids. However, Geoffrey-Perez and colleagues countered by 
reporting that there was an absence of association between bladder cancer risk and fluid 
consumption (Geoffroy-Perez and Cordier 2001). Intuitively it remains logical that dilution 
of bladder carcinogenic contents with frequent urination would be beneficial and less 
expensive practice.  
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4.2 Fat and caloric intake 
In the Spanish study, Riboli and associates reported an association between fat consumption 
and urothelial cancer that showed a 2-fold increase in cancer incidence (Riboli, Gonzalez et 
al. 1991). Surveillance Epidemiology and End Results (SEER) population-based study data 
provided further evidence that fat rich diets are associated with an increase in incidence of 
UC (OR 2.24 for the highest quartile, 95% CI, 1.25-4.03, P=0.006) (Bruemmer, White et al. 
1996). A Swedish study suggests a dose dependent effect of fat diet on the incidence of UC 
(Steineck, Hagman et al. 1990). In a meta-analysis of 36 studies evaluating 6 dietary variables 
in relation to UC, Steinmaus and group reported a positive association between intake of fat 
and UC (Relative ratio, RR 1.37, 95% CI, 1.16-1.62), but not with meat consumption (RR 1.08, 
95% CI, 0.82-1.42) (Steinmaus, Nunez et al. 2000). However, there was no positive 
association between total caloric intake and UC over 12 years in the Health Professional 
Follow-Up Study (Michaud, Spiegelman et al. 2000). The traditional flaws of epidemiologic 
studies certainly affect the results of these studies including recall bias and lack of 
prospective randomized data. Other confounding factors include concomitant increased in 
caloric intake with increased fat intake. Despite these drawbacks of the reports, decreased 
fat intake should be a recommendation for prevention strategy of UC.  
4.3 Green tea 
Drinking tea has been reported to confer protective health benefits which include 
prevention of human cancers including prostate and bladder cancers (Trevisanato and Kim 
2000). 
The polyphenols found in green tea are potent antioxidants; they also inhibit ornithine 
decarboxylase which is an enzyme that promotes tumor proliferation via nucleic acid 
regulation (Steele, Kelloff et al. 2000). The incidence of UC in Asian populations with 
increased tea consumption is lower than in North America; a weak inverse relationship 
between tea intake and UC has been reported in one epidemiological study (Kemberling, 
Hampton et al. 2003). In order to settle the ongoing controversy, NCI-sponsored phase 2 and 
3 clinical trials are in progress (National Cancer Institute). 
4.4 Soy 
Soy products have potential apoptotic and anti-angiogenic actions attributable to their high 
isoflavone content (Su, Yeh et al. 2000).Their role in UC chemoprevention, unlike in prostate 
cancer, has yet to be elucidated. Contrary Su and group reported in a Singapore-based 
population study an increased UC incidence associated with high consumption of soy food 
(95% CI, 1.1-5.1) (Su, Yeh et al. 2000).This risk was independent of smoking. There is no data 
yet favoring recommendation of soy for chemoprevention in UC.  
5. Bladder cancer chemoprevention strategies: Pharmacologic agents  
5.1 Vitamins and supplements 
Researchers have long regarded vitamins and the so-called micronutrients as ideal agents 
for primary chemoprevention for human cancer. For the reasons discussed earlier primary 
chemoprevention in human bladder cancer lacks an effective agent as well as evidence-
based data to encourage wide clinical practice.  
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5.1.1 Vitamin A and analogues 
Epidemiologic data in humans regarding the efficacy of Vitamin A are inconsistent. Many 
reports have suggested a therapeutic benefit from retinoid supplements. Data includes the 
SEER database controlled study, which compared 1592 UC participants to a matched 
neighborhood controls (Castelao, Yuan et al. 2004). Carotenoids were found to be beneficial 
in previous or current smokers. Authors using fenretinide in a randomized study failed to 
demonstrate the difference in tumor detection by flow cytometry between treatment and 
placebo arms in a sample of 99 participants (Decensi, Torrisi et al. 2000). Fenretinide is a 
synthetic derivative of Vitamin A which is FDA approved for the treatment of macular 
degeneration, and cystic fibrosis; and it has been investigated for use in cancer 
chemoprevention. Studer and group treated 90 Ta and T1 patients after transurethral 
resection with etretinate (Studer, Jenzer et al. 1995). They observed that time to first tumor 
occurrence was the same in both treatment and placebo groups, however, time to second 
tumor occurrence was lower for treatment group versus placebo (20.3 v 12.7 months, 
P>0.006). The data suggests that the agent acts not on established bladder cancer, but acts to 
prevent new cancer. Vitamin A overdose is known to cause low blood pressure, fever, and 
pulmonary insufficiency. Synthetic formulations of vitamin A are reported to show less 
significant adverse events (Sporn and Lippman 2003). 
Sabichi and colleagues reported on a negative Phase III chemoprevention trial that showed 
that Fenretinide was well tolerated but failed to show a significant reduction in high 
incidence of recurrent non-muscle invasive urothelial bladder cancer (Sabichi, Lerner et al. 
2008). The authors speculated that variable of dosing and scheduling could have affected the 
clinical results. However, data from other randomized clinical studies in contralateral breast 
cancer, ovarian cancer and oral premalignancy suggested preventative benefit of fenretinide 
in these malignancies (Sporn and Lippman 2003). In another clinical prevention trial in 
bladder cancer, this agent was reported as being less toxic and more efficacious than the 
retinoid etretinate (Sabichi, Lerner et al. 2008).  
5.1.2 Vitamin B6 (Pyridoxine) 
Vitamin B6 has been evaluated in patients with history of recurrent UC. The Veterans 
Administration Study by Byar and group showed that Pyridoxine provided the best benefit 
(P=0.03) in a 3-ARM trial of intravesical thiotepa, Pyridoxine and placebo in 121 patients 
with history of recurrent NMIUBC (Byar and Blackard 1977). The authors also showed that 
the efficacy of Pyridoxine was equivalent to that of thiotepa. The theory was that Pyridoxine 
would correct the abnormalities of Tryptophan metabolism often found in patients with 
bladder cancer. This data was not supported in a large study of 291 patients in the EORTC 
trial of Pyridoxine versus placebo with neither treatment showing any benefit in preventing 
occurrence or recurrence of UC (Newling, Robinson et al. 1995). 
5.1.3 Vitamin C 
Ascorbic acid (Vitamin C) is a potent antioxidant reported in human epidemiological studies 
to prevent UC (Shibata, Paganini-Hill et al. 1992; Michaud, Spiegelman et al. 2000). The 
effect is also thought to be dose dependent, with improved benefit associated with higher 
consumption (Shibata, Paganini-Hill et al. 1992; Michaud, Spiegelman et al. 2000). Favorable 
reports are inconsistent in large cohorts. 
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5.1.4 Vitamin E 
Vitamin E is another antioxidant and is capable of reducing the carcinogenic N-nitroso 
compounds. Vitamin E has been reported in multiple studies to show benefit in reducing 
incidence of UC (Bruemmer, White et al. 1996; Michaud, Spiegelman et al. 2000). However, a 
meta-analysis by Miller and associates showed a potential increased in all-cause mortality 
associated with Vitamin E consumption (Miller, Pastor-Barriuso et al. 2005). This finding has 
dampened enthusiasm in the use of Vitamin E in chemoprevention for UC. 
5.1.5 Selenium  
There is no data yet suggesting a chemopreventive role for this oligoelement in UC. 
5.1.6 Mega dose vitamins 
Vitamins and dietary supplements/modifications have received slightly skewed publicity 
as alternative protective strategies against bladder cancer (Kamat and Lamm 2002). 
Individual vitamins including Vitamin A, and its analogues, Vitamin B6 (pyridoxine), 
Vitamin C, Vitamin E have been studied individually, reported and proposed as dietary 
supplements to prevent bladder cancer.as discussed above (Byar and Blackard 1977; 
Shibata, Paganini-Hill et al. 1992; Newling, Robinson et al. 1995; Studer, Jenzer et al. 1995; 
Decensi, Torrisi et al. 2000; Kamat and Lamm 2002; Castelao, Yuan et al. 2004; Miller, 
Pastor-Barriuso et al. 2005; Sabichi, Lerner et al. 2008). However, Lamm et al. combined 
mega doses of Vitamins A(40,000U), B6(100mg), C(2000 mg), E(400U) and Zinc (90mg) in 
a randomized 2x2 factorial design study in which 65 patients were randomized to receive 
intraderrmal BCG (Lamm, Riggs et al. 1994). Participants who demonstrated a response to 
induction intravesical BCG, were randomized to receive either Megadose vitamins or 
recommended daily allowance (RDA).The use of intradermal BCG did not appear to affect 
the clinical outcome. The Mega-dose vitamins treatment group showed a 50% reduction in 
overall NMIUBC recurrence at 4 years, The fact that there was no reduction in tumor 
recurrence rate in the Megadose vitamins group in the first 10 months, would suggest that 
these supplements/agents do not affect existing tumors but hinder the formation of new 
tumors. 
5.2 Difluoromethylornithine
 
Difluoromethylornithine (DFMO) is a competitive inhibitor of ornithine decarboxylase 
(ODC) which is an enzyme that induces polyamine production necessary for tumor growth. 
A negative study was reported by Messing and associates who observed that daily oral 
supplementation of difluoromethylornithine (DFMO) compared with placebo, did not 
prevent frequent recurrence and progression of low grade NMIBC in patients who had been 
completely resected at enrollment (Messing, Kim et al. 2006). 
5.3 COX Inhibitors 
NSAID inhibit the cyclooxygenase (COX) enzyme, which breaks down arachidonic acid into 
leukotrienes and prostaglandins. Prostaglandin-2 can enhance cell proliferation, 
angiogenesis, and inhibit apoptosis (Sabichi and Lippman; Okey, Harper et al. 1998; Sporn 
and Lippman 2003). In vitro evidence suggests that there is an over expression of COX 2 
isoform in UC (Okey, Harper et al. 1998; Sporn and Lippman 2003). Theoretically, COX 2 
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isoform inhibitors could be used in chemoprevention of UC. Castelao and colleagues 
reported on a population-based, case-control study, in which they evaluated non-steroidal 
anti-inflammatory drugs (NSAIDs) in NMIUBC (Castelao, Yuan et al. 2000). This study 
found a 19% decrease in UC risk in those patients treated with oral agents, except those 
patients treated with phenacetine and pyrazolone derivatives (Castelao, Yuan et al. 2000). 
Therefore, COX-2 remains a very viable target for future evaluation in bladder cancer 
chemoprevention.  
 
Preventive 
Strategy 
Methodology Mechanism Published 
studies 
Significance Current status 
Fluid intake Mailing 
Questionnaires 
Increased fluid 
intake results in 
lowered 
cumulative 
exposure of 
urothelium 
to carcinogens  
with reduced  
risk 
 
The Health 
Professional 
Follow up 
Study  
(n = 47,903) 
High  Recommended 
(Level 4 evidence;  
Grade C 
recommendation) 
Fat and 
calorie intake 
Population based 
study (SEER) and 
meta-analysis  
of 36 studies 
evaluating 6 
dietary variables 
in relation to UC
2-fold increase in 
cancer with 
increased fat 
consumption 
Riboli et al & 
SEER 
studies: 
positive 
correlation; 
Health 
Professionals 
follow  
up study:  
no 
correlation 
 
Intermediate  Recommended 
(Level 2 evidence; 
Grade B 
recommendation) 
Green Tea Epidemiological Polyphenols 
contents of green 
tea are potent 
antioxidants;  
also inhibit 
ornithine 
decarboxylase 
which is an 
enzyme that 
promotes tumor 
proliferation via 
nucleic acid 
regulation; a weak 
inverse relationship 
between tea intake 
and UC 
 
NCI-
sponsored 
phase 2 and 
3 clinical 
trials are in 
progress 
Low  Recommended 
(Level 4 evidence; 
Grade C 
recommendation) 
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Preventive 
Strategy 
Methodology Mechanism Published 
studies 
Significance Current status 
Soy Popublation 
based 
potential apoptotic 
and action 
attributable to the 
high isoflavone 
content; no data yet 
favoring 
recommendation 
 
Singapore-
based 
population 
study 
Very low Not 
recommended 
Smoking Population based Smoking cessation 
correlates with 
decreased 
incidence 
Population 
based 
High - most 
cost-effective 
measure in 
bladder cancer 
prevention 
strategy 
 
Highly 
recommended 
(Level 3 evidence; 
Grade B 
recommendation) 
Vitamin A compared 1592 
UC participants 
to a matched 
neighborhood 
controls 
Agent does act not 
on established 
bladder cancer, 
but prevents new 
cancer 
SEER 
database 
controlled 
study 
Low - lacks an 
effective agent 
as well as 
evidence-based 
data to 
encourage 
wide clinical 
practice  
 
Recommended 
(Level 3 evidence; 
Grade B 
recommendation) 
Vitamin B6 3-arm trial; 
placebo 
controlled trial 
Pyridoxine 
provided the best 
benefit (P=0.03) in 
a 3-Arm trial of 
intravesical 
thiotepa, placebo, 
and Pyridoxine; 
however, this data 
was not supported 
in EORCT trial 
(n=291) of 
Pyridoxine versus 
placebo, both 
showing no benefit 
in preventing 
occurrence or 
reoccurrence 
 
The Veterans 
Administrati
on Study 
(Byar et al) 
Intermediate  Not 
recommended 
Vitamin C Human 
epidemiological 
studies 
potent antioxidant; 
effect dose 
dependent, better 
with higher 
consumption 
 
Large cohort 
studies 
Inconsistent  Not 
recommended 
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Preventive 
Strategy 
Methodology Mechanism Published 
studies 
Significance Current status 
Vitamin E meta-analysis  antioxidant 
capable of 
reducing 
carcinogenic  
N-nitroso 
compounds in 
urothelium 
 
Miller et al. Potential 
increase in all-
cause mortality 
with Vitamin E 
consumption 
Not 
recommended 
Selenium No data no data yet 
suggesting a 
chemopreventive 
role for this 
oligoelement  
in UC 
 
No data N/A Not 
recommended 
Megadose 
vitamins 
randomized 2x2 
design study in 
which 65 patients 
were 
randomized to 
received 
intraderrmal 
BCG or not,  
and also 
randomized  
after response  
to induction 
intravesical  
BCG to receive 
Megadose 
vitamins versus 
daily 
recommended 
daily  
allowance 
 
Possible anti-
oxidant role 
Small trial 
from a single 
institution  
Mega-dose 
vitamins-
treated group 
showed a 50% 
reduction in 
overall NMIBC 
recurrence at 4 
years 
Not 
recommended 
Difluorometh
ylornithine 
(DFMO) 
Messing et al DFMO is a 
competitive 
inhibitor of 
ornithine 
decarboxylase that 
induces polyamine 
production 
necessary for 
tumor growth 
Negative 
study 
daily oral 
supplementatio
n vs. placebo, 
did not prevent 
recurrence and 
progression  
of low grade 
NMIBC 
following  
prior  
TUR-BT  
 
Not 
recommended 
www.intechopen.com
The Potential Role of Chemoprevention  
in the Management of Non-Muscle Invasive Bladder Urothelial Carcinoma 
 
257 
Preventive 
Strategy 
Methodology Mechanism Published 
studies 
Significance Current status 
COX 
inhibitors 
Castelao et al.  Prostaglandin-2 
can enhance cell 
proliferation, 
angiogenesis, and 
inhibit apoptosis. 
In vitro evidence 
suggests over 
expression of COX 
2 isoform in UC 
a 
population-
based, case-
control study 
- NSAIDs in 
NMIUBC 
showed 
a19% 
decrease in 
UC risk in 
those treated 
with oral 
NSAIDs 
(except 
phenacetine 
and 
pyrazolone 
derivatives) 
 
COX-2 remains 
a very viable 
target in 
bladder cancer 
chemopreventi
on 
Recommended 
(non-evidence 
based) 
Table 1. Summary of Reports (discussed above) of various Chemopreventative Strategies 
(refs:28-51) 
6. Future research and experimental cancer chemoprevention 
Research continues intensely in the evaluation of pharmaceutical agents for 
chemoprevention in bladder cancer. However, dietary supplement, multivitamins and 
phytochemicals/botanical agents are being evaluated in the prevention of many human 
cancers (Byar and Blackard 1977; Shibata, Paganini-Hill et al. 1992; Lamm, Riggs et al. 
1994; Newling, Robinson et al. 1995; Studer, Jenzer et al. 1995; Castelao, Yuan et al. 2000; 
Decensi, Torrisi et al. 2000; Michaud, Spiegelman et al. 2000; Kamat and Lamm 2002; 
Castelao, Yuan et al. 2004; Miller, Pastor-Barriuso et al. 2005; Messing, Kim et al. 2006; 
Sabichi, Lerner et al. 2008). Investigators have reported on results of screening strategies 
for synthetic pharmaceuticals in an experimental bladder cancer prevention model using 
the chemically-induced rat bladder tumor model (Sindhwani, Hampton et al. 2001; Lubet, 
You et al. 2006; Park, Kim et al. 2006; Tian, Wang et al. 2008; Parada, Reis et al. 2011).  
They reported that low dose aspirin and resveratrol were least effective in preventing 
large tumor formation, while naproxen and Iressa were most effective (Lubet, You et al. 
2006). 
In recent years there has been a substantial interest in the application of botanically 
derived phytochemicals to reduce the incidence of variety of human tumors. Intense 
research is ongoing to provide evidence-based recommendations to incorporate plant 
foods or botanical products or dietary modifications into the practice of clinical cancer 
chemoprevention. There is the salient speculation that Curcumin, a very popular Indian 
food spice, derived from the rhizome plant called curcuma longa Linn (Zingiberaceae), 
has been responsible for lower incidence of urothelial malignancies (Sindhwani, Hampton 
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et al. 2001; Tian, Wang et al. 2008)and lower rate of colorectal cancer (Tian, Wang et al. 
2008) in the populations that consume Curcumin as a staple part of their diet (Sindhwani, 
Hampton et al. 2001; Tian, Wang et al. 2008). Investigators have reported on Curcumin 
induced apoptosis in MBT-2 cells[56] G2/M cell cycle arrest in T-24 cells (Sindhwani, 
Hampton et al. 2001; Tian, Wang et al. 2008). Curcumin inhibition of intravesical tumor 
implant in mouse model (Sindhwani, Hampton et al. 2001) and prevention of OH-BBN 
induced bladder carcinogenesis in rodent, as well as inhibition of tumor development and 
growth in an intravesical murine bladder model (Sindhwani, Hampton et al. 2001; Tian, 
Wang et al. 2008). 
Seventy-five percent of all pharmaceuticals were discovered by studying the use of plants in 
traditional medicine. Of the 92 antitumor drugs approved by the FDA between 1983 and 
1994, 62 (67%) were either of natural origin or based on a natural compound (Chung, 
Anscher et al. 2001).  
7. Conclusions and clinical practice suggestions  
Bladder cancer is a common, but serious health problem globally. It is immensely impacted 
by environmental carcinogens, tobacco smokes, and infectious etiologies in endemic areas. 
The bladder urothelial cancer special features which include its susceptibility; 
carcinogenesis; frequent recurrences, and clinical presentation favor it as an ideal cancer for 
chemoprevention. Unfortunately, in bladder cancer there are still no definite interventions 
that have been shown to be effective, and research in this area has yielded no evidence-
based data to inform on strategies for systematic practice of bladder cancer prevention. The 
positive data from the clinical trials with vitamins individually or in combinations suggest 
that these agents might act not on established bladder cancer, but act to prevent occurring of 
new cancers, probably by hindering promotion of altered cells to overt cancer. Cessation of 
smoking will always remain the lofty but impractical goal of prevention strategies in 
urothelial bladder cancer; however, a plausible paradigm would suggest a chemoprevention 
strategy that should begin with the population approach that advocates a dietary program 
of increased consumption of fruits and vegetables which have been reported to reduce 
general cancer risk. The at–risk individual would embark on additional programs to 
reduce/eliminate the intensity of cumulative exposure to the carcinogens, dilution and 
elimination of bladder content by drinking plenty of water and urinating frequently, 
followed by introduction of the specific chemopreventive agent(s), probably in combination 
with the vitamins. 
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